Fabry Disesase clinical trials at UCLA
1 research study open to eligible people
Showing trials for
HM15421/GC1134A in Patients With Fabry Disease
open to eligible people ages 18 years and up
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Los Angeles, California and other locations
Our lead scientists for Fabry Disesase research studies include Anjay Rastogi, MD, PhD.
Last updated: